You did everything right. You talked to your doctor, you qualified on paper, you got the prescription. Then a letter showed up — or worse, the pharmacy counter just said no — and suddenly you are holding a piece of paper full of words like formulary and medical necessity and step therapy, none of which anyone has ever explained to you.
Here is the part nobody tells you: a GLP-1 denial is not one thing. There are several completely different reasons a plan says no, they are not equally serious, and they are not equally fixable. Some denials are a closed door. Some are a form that was filled out wrong. They can look almost identical on paper.
So before you write a single word of an appeal, it is worth understanding what actually happened. That is what this article is for.
This is the thing that stings the most, so let's get it out of the way.
When your plan denies a prescription, that decision usually did not come from your insurance company's medical staff weighing your chart. It came from a formulary — a list, negotiated in advance, of which drugs your plan pays for and under what conditions.
That list is typically built by a pharmacy benefit manager, or PBM. The PBM is a middleman company your plan hires to run its drug benefit. It negotiates prices with manufacturers, decides which drugs sit on which pricing tier, and sets the rules you have to clear before a drug gets paid for.
What that means practically: the first "no" you get is usually a rules check, not a medical opinion. Your prescription was measured against a list of criteria, and something did not match. That is frustrating, but it is also good news — because rules can be answered with documentation in a way that a genuine medical disagreement cannot.
If you remember one thing from this article, make it this one.
Several GLP-1 medications are the exact same molecule sold under two different brand names, approved for two different purposes — and your plan very likely treats those two brands completely differently.
Same active ingredient. Different label. And a plan that covers one can absolutely refuse the other, because what it is really covering is the indication — the medical reason the drug is approved for — not the molecule.
This is why you will hear someone say "my insurance covers Ozempic but denied Wegovy" and think it must be a mistake. It usually isn't. Many plans cover GLP-1s for diabetes and specifically exclude them for weight loss. Those are two separate decisions in the plan document, and they are made for cost reasons, not clinical ones.
It is also why "which drug am I actually being prescribed, and for which approved use" is the first question worth answering when you are trying to understand a denial.
Almost every GLP-1 denial falls into one of these buckets. They are not the same, and telling them apart changes everything about what you do next.
This is the plan saying: we do not cover this category of drug at all. Not for you, not for anyone on this plan, no matter how well you document it. Weight-loss medications are one of the most commonly excluded categories in employer coverage, often written into the plan as a specific carve-out.
This is the hardest kind of no, because there is no clinical argument to make. The drug isn't being judged — it was never in the benefit to begin with. Appeals against a true exclusion rarely succeed on medical grounds.
But it is worth confirming that an exclusion is really what you're facing, because it is also the denial most often assumed and least often verified. Which brings us to the ones that look similar and behave very differently.
Here the drug is covered by your plan — you just haven't yet proven you meet the conditions attached to it. Prior authorization means your plan requires sign-off before it will pay.
Typical conditions include a BMI threshold, a documented related health condition, evidence you've tried lifestyle changes, or a specific diagnosis code on the paperwork.
This is the most winnable category by a wide margin, because these denials are frequently about missing information rather than a real disagreement. A chart note that didn't get attached. A diagnosis code that didn't make it onto the form. A BMI recorded at a visit two years ago instead of last month. The plan didn't say you don't qualify — it said it wasn't shown that you do.
Sometimes called "fail first." Your plan will cover the drug, but only after you've tried a cheaper option and it hasn't worked for you.
These are often winnable too, especially when there's a documented reason the required first-line drug isn't appropriate for you — you already tried it, you had a bad reaction, or there's a medical reason it's a poor fit. The appeal isn't arguing that step therapy is unfair; it's showing that you've already satisfied it or that it doesn't apply to your situation.
Before you conclude you've been denied at all, rule out the two cheapest problems to fix: a quantity or dose limit, where the drug is covered but not at the amount prescribed, and a non-formulary or tier placement issue, where the drug is covered at a much higher cost tier rather than refused. Both can read like a denial at the pharmacy counter and neither is one.
Not sure which kind of denial you're holding? The GLP-1 Insurance Appeal Kit walks you through reading your denial letter line by line, matching the reason to the right records, and building the appeal — with letter templates for you and your provider, printable worksheets, a call log, and a plain-English glossary. Instant PDF download, $19.99. Get the kit →
Two women can get an identical denial letter for the identical drug and have completely different paths forward, because they have different kinds of coverage.
This is where most denials happen, and the trend is not in your favor. In a Business Group on Health survey of 127 large employers covering roughly 8.7 million people, coverage of GLP-1s for obesity fell from 72% in 2025 to 60% in 2026. Fourteen percent of employers had dropped the coverage or planned to by 2027, up from 10% earlier in the year, and another 24% have never offered it and aren't considering it.
The reason is blunt: these drugs commonly run $1,000 to $1,500 a month, and employers are often paying most or all of that. Some plans aren't dropping coverage outright but are tightening it — raising BMI thresholds, adding clinical criteria, narrowing who qualifies.
There's also a distinction inside employer coverage worth knowing. Some employers buy insurance from a carrier; others pay claims with their own money and simply hire a carrier to administer the plan. The second kind is called self-funded, and it's governed by federal law rather than your state's insurance rules. Your member documents will tell you which you have, and it affects which agency oversees your plan if things go sideways.
Medicare historically did not cover drugs prescribed purely for weight loss. That changed this year.
As of July 1, 2026, Medicare runs a temporary program covering certain weight-loss GLP-1s for Part D enrollees at a $50 monthly copay, scheduled to run through the end of 2027. It covers Foundayo tablets, Wegovy, and Zepbound KwikPens — notably not Ozempic, and not Zepbound single-dose vials or pens.
Eligibility runs on BMI plus condition: a BMI of 35 or higher; or 30 and above with heart failure, uncontrolled high blood pressure, or chronic kidney disease; or 27 and above with prediabetes or a history of heart attack, stroke, or peripheral artery disease. Your prescriber has to submit prior authorization and certify that you're using it alongside a diet and exercise program.
One catch worth knowing up front: that $50 copay does not count toward your Part D deductible or your out-of-pocket cap.
Medicaid coverage of GLP-1s for weight management varies enormously by state — some cover it with prior authorization, some don't cover it at all. Marketplace plans vary by state and by the specific plan you chose. In both cases the answer genuinely depends on where you live, so your plan's own drug list is the only reliable source.
You're really answering three questions, in this order.
Is it an exclusion, or is it criteria? This is the fork in the road. A plan that excludes the whole category is a different problem from a plan that covers the drug and wasn't convinced you qualify. Your denial notice is required to state the specific reason, and your plan documents will say whether weight-loss medications are excluded. If it's criteria, you're in much better territory than you think.
Does the reason given actually match your situation? Read the stated reason against your own records. Denials citing a BMI you've since exceeded, a condition you do have documented, or a drug you've already tried are extremely common — and they are errors of information, not verdicts.
Is there a review stage beyond your insurer? For many plans, if an internal appeal fails, you can request an external review — an independent organization, not your insurance company, looks at the case. It applies to denials involving medical judgment, and the decision is binding on the plan. This is the part most people never get to, and it exists precisely because insurers shouldn't be the last word on their own denials.
If the answer to any of those points toward "criteria," your denial is likely the kind that responds to a well-documented appeal.
Honesty matters more than hope here. If your plan carries a true, written exclusion on weight-loss medications, an appeal arguing medical necessity is usually not the strongest use of your energy. Some other paths people look at in that situation: asking your prescriber whether a different GLP-1 with a different approved indication fits your actual diagnosis, manufacturer savings and patient assistance programs, and — if your coverage comes through work — raising it during open enrollment, when plan design is still being decided.
You'll find more of what I lean on for the GLP-1 journey over on The Pretty Well Resources.
None of those are guarantees. But knowing which fight you're in beats fighting the wrong one.
Understanding why you were denied is the first half. The second half is the paperwork — matching the denial reason to the right records, getting the documentation in the right order, and putting it in front of the right person before the window closes.
That's exactly what the GLP-1 Insurance Appeal Kit walks you through: a plain-English, step-by-step process with letter templates for you and your provider, a call log, printable worksheets, and a glossary for every piece of insurance vocabulary nobody bothered to teach you.
You don't have to become an insurance expert. You just have to be organized, and know which kind of no you got.
Get the GLP-1 Insurance Appeal Kit — $19.99 →
This article is educational information, not medical, legal, or insurance advice. It is not affiliated with any insurer, drug manufacturer, or government program. Coverage rules change and vary by plan, state, and year — your own plan documents and your insurer are the authority on your coverage. Talk with your healthcare provider about your treatment, and a qualified professional about legal or insurance questions. No appeal outcome is guaranteed.
